TNX 100

Drug Profile

TNX 100

Alternative Names: 5D12; Anti-CD40 monoclonal antibody 5D12

Latest Information Update: 08 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chiron Corporation
  • Developer Tanox
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action CD40 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Crohn's disease; Transplant rejection

Most Recent Events

  • 03 Aug 2007 Tanox has been acquired by Genentech
  • 01 Oct 2004 Discontinued - Phase-I for Crohn's disease in USA (IV)
  • 01 Oct 2004 Discontinued - Preclinical for Autoimmune disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top